Candidiasis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Candidiasis – Drugs In Development, 2023’, provides an overview of the Candidiasis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Candidiasis
- The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects
- The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Candidiasis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Candidiasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
60 Degrees Pharmaceuticals IncAbGenics Life Sciences Pvt Ltd
AimMax Therapeutics Inc
Autoimmune Technologies LLC
Bakker Medical Srl
Basilea Pharmaceutica Ltd
Beta Pharma Inc
Biocidium Biopharmaceuticals Inc
Biokawthar Technologies SAS
Biomendics LLC
Biosergen AS
Cidara Therapeutics Inc
Cincinnati Children's Hospital Medical Center
Cisen Pharmaceutical Co Ltd
Concerto Biosciences Inc
CSPC Pharmaceutical Group Ltd
Dare Bioscience Inc
Destiny Pharma Plc
Female Healthcare Purna
Gedeon Richter Plc
General Biologicals Corp
Georgetown University
Grupo Ferrer Internacional SA
HC Synthetic Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu ProteLight Pharmaceutical & Biotechnology Co Ltd
Kansas State University
King's College London
Louisiana State University Health Sciences Center New Orleans
Matinas BioPharma Holdings Inc
MicroRid Technologies Inc
Mycovia Pharmaceuticals Inc
Nanomerics Ltd
Next Science Ltd
Nosopharm SAS
Oryn Therapeutics
Osel Inc
Pacgen Life Science Corp
Pfizer Inc
Profem GmbH
Profounda Inc
Pulmocide Ltd
Pulmonomy Inc
R-Pharm
REYON Pharmaceutical Co Ltd
Riptide Bioscience Inc
Sano Chemicals Inc
SaNOtize Research and Development Corp
Satellos Bioscience Inc
Scynexis Inc
Second Military Medical University
Stadius Biopharma LLC
State University of New York at Buffalo
Stony Brook University
The Lundquist Institute
Toltec Pharmaceuticals LLC
University of Aberdeen
University of Toulouse
University of Wisconsin Madison
Wellstat Vaccines LLC